- ISSN 1672-5069
- CN 34-1270/R
- CODEN SGZHBF
JOURNAL OF PRACTICAL HEPATOLOGY ›› 2018, Vol. 21 ›› Issue (2): 170-176.doi: 10.3969/j.issn.1672-5069.2018.02.006
Previous Articles Next Articles
National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association
Received:2018-01-02
Online:2018-03-10
Published:2018-03-19
Contact:
Li Youming,E-mail:National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 170-176.
| [1] 酒依赖与肝病问题调查协作组.中国9个城市4种职业人群酒依赖协作研究(一)(二)[J]. 中国心理卫生杂志,1992,6:112. [2] 陈士林,孟晓丹,王炳元,等. 辽宁省部分城市酒精性肝病流行现状调查[J]. 实用肝脏病杂志,2010,13(6):428-430,435. DOI:10.3969/j.issn.1672-5069.2010.06.010. [3] Wang H,Ma L,Yin Q,et al.Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China[J]. Alcohol Clin Exp Res,2014,38(4):1035-1041. DOI:10.1111/acer.12321. [4] 黄顺玲,戴水奇,张雪红,等. 湖南省酒精性肝病流行病学调查概况[J]. 中国医师杂志,2005,7(3):426-427. DOI:10.3760/cma.j.issn.1008-1372.2005.03.080. [5] 鲁晓岚,陶明,罗金燕,等. 饮酒与肝病流行病学调查[J].中华肝脏病杂志,2002,10(6):467-468. DOI:10.3760/j.issn:1007-3418.2002.06.029. [6] 厉有名,陈卫星,虞朝辉,等. 浙江省酒精性肝病流行病学调查概况[J]. 中华肝脏病杂志,2003,11(11):647-649. DOI:10.3760/j.issn:1007-3418.2003.11.002. [7] Zhou YJ,Li YY,Nie YQ,et al.Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol,2007,13(47):6419-6424. [8] 姚锦慧,赵秋冬,熊鹏芬,等. 云南元江少数民族酒精性肝病流行病学调查[J].胃肠病学和肝病学杂志,2011,20(12):1137-1139. DOI:10.3969/j.issn.1006-5709.2011.12.021. [9] 全国酒精性肝病调查协作组.全国酒精性肝病的多中心调查分析[J].中华消化杂志,2007,27(4):231-234.DOI:10.3760/j.issn:0254-1432.2007.04.005. [10] 刘阳,迟宝荣.酒精性肝硬化237例临床分析[J].吉林医学,2004,25(4):40-42.DOI: 10.3969/j.issn.1004-0412.2004.02.016. [11] 王辉,王江滨. 肝炎病毒感染与酒精性肝硬化关系的研究(附182例酒精性肝病临床病例报告)[J].白求恩医科大学学报,1998,24(6):652-653. [12] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108. DOI:10.1002/hep.27406. [13] Rehm J,Taylor B,Mohapatra S,et al.Alcohol as a risk factor for liver cirrhosis:a systematic review and meta-analysis[J]. Drug Alcohol Rev,2010,29(4):437-445. DOI:10.1111/j.1465-3362.2009.00153.x. [14] Shen Z,Li YM,Yu CH,et al.Risk factors for alcohol-related liver injury in the island population of China:a population-based case-control study[J].World J Gastroenterol,2008,14(14):2255-2261. [15] Becker U,Deis A,Sorensen TI,et al.Prediction of risk of liver disease by alcohol intake,sex,and age:a prospective population study[J].Hepatology,1996,23(5):1025-1029. DOI: 10.1002/hep.510230513. [16] Corrao G,Bagnardi V,Zambon A,et al.A meta-analysis of alcohol consumption and the risk of 15 diseases[J]. Prev Med,2004,38(5):613-619. DOI:10.1016/j.ypmed.2003.11.027. [17] Kamper-Jørgensen M,Grønbaek M,Tolstrup J,et al.Alcohol and cirrhosis:dose-response or threshold effect[J]. J Hepatol,2004,41(1):25-30. DOI:10.1016/j.jhep.2004.03.002. [18] Becker U,GrønbaekM,Johansen D,et al. Lower risk foralcohol-induced cirrhosis in wine drinkers[J]. Hepatology,2002,35(4):868-875. DOI:10.1053/jhep.2002.32101. [19] Jiang H,Livingston M,Room R,et al.Alcohol consumption and liver disease in Australia:a time series analysis of the period 1935-2006[J]. Alcohol Alcohol,2014,49(3):363-368. DOI: 10.1093/alcalc/agt143. [20] Lu XL,Luo JY,Tao M,et al.Risk factors for alcoholic liver disease in China[J]. World J Gastroenterol,2004,10(16):2423-2426. [21] Hatton J,Burton A,Nash H,et al.Drinking patterns,dependency and life-time drinking history in alcohol-related liver disease[J].Addiction,2009,104(4):587-592. DOI: 10.1111/j.1360-0443.2008.02493.x. [22] Sato N,Lindros KO,Baraona E,et al.Sex difference in alcohol-related organ injury[J]. Alcohol Clin Exp Res,2001,25(5 Suppl ISBRA):40S-45S. [23] Eagon PK.Alcoholic liver injury:influence of gender and hormones[J]. World J Gastroenterol,2010,16(11):1377-1384. [24] Baraona E,Abittan CS,Dohmen K,et al.Gender differences in pharmacokinetics of alcohol[J]. Alcohol Clin Exp Res,2001,25(4):502-507. [25] Wickramasinghe SN,Corridan B,Izaguirre J,et al.Ethnic differences in the biological consequences of alcohol abuse:a comparison between south Asian and European males[J]. Alcohol Alcohol,1995,30(5):675-680. [26] Borràs E,Coutelle C,Rosell A,et al.Genetic polymorphism of alcohol dehydrogenase in europeans:the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1[J]. Hepatology,2000,31(4):984-989. [27] Yu C,Li Y,Chen W,et al.Genotype of ethanol metabolizing enzyme genes by oligonucleotide microarray in alcoholic liver disease in Chinese people[J].Chin Med J (Engl),2002,115(7):1085-1087. [28] Mendenhall C,Roselle GA,Gartside P,et al.Relationship of protein calorie malnutrition to alcoholic liver disease:a reexamination of data from two Veterans Administration Cooperative Studies[J].Alcohol Clin Exp Res,1995,19(3):635-641. [29] Leevy CM,Moroianu SA.Nutritional aspects of alcoholic liver disease[J].Clin Liver Dis,2005,9(1):67-81. DOI:10.1016/j.cld.2004.11.003. [30] Mezey E.Dietary fat and alcoholic liver disease[J]. Hepatology,1998,28(4):901-905. DOI: 10.1002/hep.510280401. [31] Williams R.Global challenges in liver disease[J]. Hepatology,2006,44(3):521-526. DOI:10.1002/hep.21347. [32] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J]. 中华肝脏病杂志,2006,14(3):164-166. DOI:10.3760/j.issn:1007-3418.2006.03.002. [33] Bush K,Kivlahan DR,Mcdonell MB,et al.The AUDIT alcohol consumption questions(AUDIT-C):an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test[J].Arch Intern Med,1998,158(16):1789-1795. [34] Soderstrom CA,Smith GS,Kufera JA,et al.The accuracy of the CAGE,the Brief Michigan Alcoholism Screening Test,and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholism[J].J Trauma,1997,43(6):962-969. [35] Chen CH,Huang MH,Yang JC,et al.Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan[J]. J Gastroenterol Hepatol,2007,22(9):1482-1489.DOI:10.1111/j.1440-1746.2006.04615.x. [36] Conigrave KM,Degenhardt LJ,Whitfield JB,et al.CDT,GGT, and AST as markers of alcohol use:the WHO/ISBRA collaborative project[J]. Alcohol Clin Exp Res,2002,26(3):332-339. [37] Yersin B,Nicolet JF,Dercrey H,et al.Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin,gamma-glutamyltransferase,and mean corpuscular volume[J]. Arch Intern Med,1995,155(17):1907-1911. [38] Majhi S,Baral N,Lamsal M,et al.De Ritis ratio as diagnostic marker of alcoholic liver disease[J]. Nepal Med Coll J,2006,8(1):40-42. [39] Nyblom H,Berggren U,Balldin J,et al.High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking[J]. Alcohol Alcohol,2004,39(4):336-339. DOI: 10.1093/alcalc/agh074. [40] Bardou-Jacquet E,Legros L,Soro D,et al.Effect of alcohol consumption on liver stiffness measured by transient elastography[J]. World J Gastroenterol,2013,19(4):516-522. DOI:10.3748/wjg.v19.i4.516. [41] Bensamoun SF,Leclerc GE,Debernard L,et al.C utoff values for alcoholic liver fibrosis using magnetic resonance elastography technique[J].Alcohol Clin Exp Res,2013,37(5):811-817. DOI: 10.1111/acer.12025. [42] d'Assignies G,Ruel M,Khiat A,et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods[J].Eur Radiol,2009,19(8):2033-2040. DOI: 10.1007/s00330-009-1351-4. [43] Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease[J]. Invest Radiol,2000,35(5):319-324. [44] Ataseven H,Yildrim MH,Yalniz M,et al. Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis [J]. J Hepatol,2003,38 Suppl 2:A4177. [45] Farrell GC,George J,Pauline de la M,et al. Fatty liver disease: NASH and related disorders. Oxford:Blsckwell Publishing,2005, 159-207. [46] Mancini M,Prinster A,Annuzzi G,et al.Sonographic hepatic-renal ratio as indicator of hepatic steatosis:comparison with (1)H magnetic resonance spectroscopy[J].Metabolism,2009,58(12):1724-1730.DOI:10.1016/j.metabol.2009.05.032. [47] Nahon P,Kettaneh A,Tengher-Barna I,et al.Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease[J]. J Hepatol,2008,49(6):1062-1068. DOI:10.1016/j.jhep.2008.08.011. [48] Sanyal AJ,American Gastroenterological Association.AGA technical review on nonalcoholic fatty liver disease[J].Gastroenterology,2002,123(5):1705-1725. [49] 沈峰,范建高.瞬时弹性成像技术在脂肪性肝病中的应用现状[J].中华肝脏病杂志,2014,22(9):643-646. DOI:10.3760/cma.j.issn.1007-3418.2014.09.002. [50] 沈峰,郑瑞丹,宓余强,等.受控衰减参数诊断脂肪肝的临界值初探:一项多中心临床研究[J].中华肝脏病杂志,2014,22(12): 926-931.DOI:10.3760/cma.j.issn.1007-3418.2014.12.010. [51] 瞬时弹性成像技术(TE)临床应用共识专家委员会. 瞬时弹性成像技术(TE)临床应用专家共识(2015年)[J].中国肝脏病杂志(电子版),2015,7(2):12-18. DOI:10.3969/j.issn.1674-7380.2015.02.002. [52] Singh S,Fujii LL,Murad MH,et al.Liver stiffness is associated with risk of decompensation,liver cancer,and death in patients with chronic liver diseases:a systematic review and meta-analysis[J].Clin Gastroenterol Hepatol,2013,11(12):1573-1584. DOI: 10.1016/j.cgh.2013.07.034. [53] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol,2015,63(1):237-264. DOI:10.1016/j.jhep.2015.04.006. [54] Castera L.Hepatitis B:are non-invasive markers of liver fibrosis reliable[J]. Liver Int,2014,34 Suppl 1:91-96. DOI: 10.1111/liv.12393. [55] Huwart L,Sempoux C,Vicaut E,et al.Magnetic resonance elastography for the noninvasive staging of liver fibrosis[J].Gastroenterology,2008,135(1):32-40. DOI:10.1053/j.gastro.2008.03.076. [56] Carithers RL Jr,Herlong HF,Diehl AM,et al.Methylprednisolone therapy in patients with severe alcoholic hepatitis.A randomized multicenter trial[J].Ann Intern Med,1989,110(9):685-690. [57] Dominguez M,Rincón D,Abraldes JG,et al.A new scoring system for prognostic stratification of patients with alcoholic hepatitis[J]. Am J Gastroenterol,2008,103(11):2747-2756. DOI:10.1111/j.1572-0241.2008.02104.x. [58] Forrest EH,Evans CD,Stewart S,et al.Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score[J]. Gut,2005,54(8):1174-1179. DOI: 10.1136/gut.2004.050781. [59] Louvet A,Naveau S,Abdelnour M,et al.The Lille model:a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids[J]. Hepatology,2007,45(6):1348-1354. DOI:10.1002/hep.21607. [60] Papastergiou V,Tsochatzis EA,Pieri G,et al.Nine scoring models for short-term mortality in alcoholic hepatitis:cross-validation in a biopsy-proven cohort[J]. Aliment Pharmacol Ther,2014,39(7):721-732. DOI:10.1111/apt.12654. [61] Said A,Williams J,Holden J,et al.Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease[J]. J Hepatol,2004,40(6):897-903. DOI:10.1016/j.jhep.2004.02.010. [62] Srikureja W,Kyulo NL,Runyon BA,et al.MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis[J]. J Hepatol,2005,42(5):700-706. DOI:10.1016/j.jhep.2004.12.022. [63] Barve A,Khan R,Marsano L,et al.Treatment of alcoholic liver disease[J]. Ann Hepatol,2008,7(1):5-15. [64] European Association for the Study Of Liver. EASL clinical practical guidelines:management of alcoholic liver disease[J].J Hepatol,2012,57(2):399-420. DOI:10.1016/j.jhep.2012.04.004. [65] Tilg H,Day CP.Management strategies in alcoholic liver disease[J]. Nat Clin Pract Gastroenterol Hepatol,2007,4(1):24-34. DOI: 10.1038/ncpgasthep0683. [66] O'shea RS,Dasarathy S,Mccullough AJ,et al. Alcoholic liver disease[J]. Hepatology,2010,51(1):307-328. DOI:10.1002/hep.23258. [67] DiCecco SR,Francisco-Ziller N.Nutrition in alcoholic liver dise-ase[J]. Nutr Clin Pract,2006,21(3):245-254. DOI:10.1177/0115426506021003245. [68] McClain CJ,Barve SS,Barve A,et al.Alcoholic liver disease and malnutrition[J]. Alcohol Clin Exp Res,2011,35(5):815-820.DOI:10.1111/j.1530-0277.2010.01405.x. [69] Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease[J].Aliment Pharmacol Ther,2003,18(4):357-373. [70] Mathurin P,O'grady J,Carithers RL,et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis:meta-analysis of individual patient data[J]. Gut,2011,60(2):255-260. DOI: 10.1136/gut.2010.224097. [71] Thursz MR,Richardson P,Allison M,et al.Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med,2015,372(17):1619-1628. DOI:10.1056/NEJMoa1412278. [72] Guerrini I,Gentili C,Nelli G,et al.A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence[J]. Subst Abuse Treat Prev Policy,2006,1:35. DOI: 10.1186/1747-597X-1-35. [73] Leggio L,Kenna GA,Ferrulli A,et al.Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease[J]. Hum Psychopharmacol,2011,26(8):554-559. DOI:10.1002/hup.1244. [74] Shpilenya LS,Muzychenko AP,Gasbarrini G,et al.Metadoxine in acute alcohol intoxication:a double-blind,randomized,placebocontrolled study[J]. Alcohol Clin Exp Res,2002,26(3):340-346. [75] Higuera-de la Tijera F,Servín-Caamano AI,Serralde-Zú?iga AE,et al. Metadoxine improves the three-and six-month survival rates in patients with severe alcoholic hepatitis[J]. World J Gastroenterol,2015,21(16):4975-4985. DOI: 10.3748/wjg.v21.i16.4975. [76] 茅益民,曾民德,陆伦根,等. 美他多辛治疗酒精性肝病的多中心、随机、双盲、安慰剂平行对照的临床研究[J]. 中华肝脏病杂志,2009,17(3):213-216. DOI:10.3760/cma.j.issn.1007-3418.2009.03.013. [77] Mato JM,Cámara J,Fernández de Paz J,et al.S-adenosylmethionine in alcoholic liver cirrhosis:a randomized,placebo-controlled,double-blind,multicenter clinical trial[J]. J Hepatol 1999,30(6):1081-1089. [78] 白冰,何清,唐尉,等. S-腺苷蛋氨酸治疗酒精性肝病的系统评价[J]. 中国肝脏病杂志(电子版),2012, 4(2):1-9. DOI:10.3969/j.issn.1674-7380.2012.02.001. [79] 邢全台,袁孟彪,高新民.思美泰治疗酒精性肝病疗效观察[J].胃肠病学和肝病学杂志,2002,11(3):239-240,242. DOI:10.3969/j.issn.1006-5709.2002.03.016. [80] Medina J,Moreno-Otero R.Pathophysiological basis for antioxidant therapy in chronic liver disease[J]. Drugs,2005,65(17):2445-2461. [81] 胡国平,刘凯,赵连三. 多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. DOI:10.3969/j.issn.1008-1704.2005.01.003. [82] 方丽华,张虹.还原型谷胱甘肽联合利加隆治疗酒精性肝炎疗效观察[J]. 肝脏,2004,9(3):181-182. DOI:10.3969/j.issn.1008-1704.2004.03.013. [83] 李丽军,李卫. 还原型谷胱甘肽治疗酒精性肝病35例临床观察[J]. 实用肝脏病杂志,2007,10(5):329-330. DOI:10.3969/j.issn.1672-5069.2007.05.018. [84] 张全海,郭树华,胡大荣,等. 国产还原型谷胱甘肽治疗酒精性肝病疗效观察[J]. 中华肝脏病杂志,2000,8(4):239-240. DOI:10.3760/j.issn:1007-3418.2000.04.015. [85] 马安林,郭新珍,刘霞,等. 双环醇与多烯磷脂酰胆碱治疗酒精性肝病的疗效比较[J]. 中华肝脏病杂志,2011,19(6):471-472. DOI:10.3760/cma.j.issn.1007-3418.2011.06.020. [86] 马安林,刘淑娥,刘霞,等. 双环醇与多烯磷脂酰胆碱治疗酒精性脂肪肝的临床病理比较[J].临床肝胆病杂志,2006,22(4):272-275. DOI:10.3969/j.issn.1001-5256.2006.04.014. [87] Mathurin P,Moreno C,Samuel D,et al.Early liver transplantation for severe alcoholic hepatitis[J]. N Engl J Med,2011,365(19):1790-1800.DOI:10.1056/NEJMoa1105703. [88] Murray KF,Carithers RL Jr,AASLD. AASLD practice guidelines:Evaluation of the patient for liver transplantation[J]. Hepatology,2005,41(6):1407-1432. DOI:10.1002/hep.20704. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
